191 related articles for article (PubMed ID: 28402931)
21. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
[TBL] [Abstract][Full Text] [Related]
22. Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment.
Musholt TJ; Musholt PB; Petrich T; Oetting G; Knapp WH; Klempnauer J
World J Surg; 2000 Nov; 24(11):1409-17. PubMed ID: 11038215
[TBL] [Abstract][Full Text] [Related]
23. Two families with an autosomal dominant inheritance pattern for papillary carcinoma of the thyroid.
Burgess JR; Duffield A; Wilkinson SJ; Ware R; Greenaway TM; Percival J; Hoffman L
J Clin Endocrinol Metab; 1997 Feb; 82(2):345-8. PubMed ID: 9024215
[TBL] [Abstract][Full Text] [Related]
24. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
[TBL] [Abstract][Full Text] [Related]
25. A Germline
Zhao Y; Yu T; Chen L; Xie D; Wang F; Fu L; Cheng C; Li Y; Zhu X; Miao G
Thyroid; 2020 Jun; 30(6):924-930. PubMed ID: 32041497
[TBL] [Abstract][Full Text] [Related]
26. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
27. Establishing a familial basis for papillary thyroid carcinoma using the Utah Population Database.
Oakley GM; Curtin K; Pimentel R; Buchmann L; Hunt J
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1171-4. PubMed ID: 24092278
[TBL] [Abstract][Full Text] [Related]
28. A Truncating Germline Mutation of
He H; Li W; Comiskey DF; Liyanarachchi S; Nieminen TT; Wang Y; DeLap KE; Brock P; de la Chapelle A
Thyroid; 2020 Feb; 30(2):204-213. PubMed ID: 31928178
[No Abstract] [Full Text] [Related]
29. A germline mutation in SRRM2, a splicing factor gene, is implicated in papillary thyroid carcinoma predisposition.
Tomsic J; He H; Akagi K; Liyanarachchi S; Pan Q; Bertani B; Nagy R; Symer DE; Blencowe BJ; de la Chapelle A
Sci Rep; 2015 Jul; 5():10566. PubMed ID: 26135620
[TBL] [Abstract][Full Text] [Related]
30. A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.
Pires C; Marques IJ; Dias D; Saramago A; Leite V; Cavaco BM
Endocrine; 2021 Sep; 73(3):588-597. PubMed ID: 33683595
[TBL] [Abstract][Full Text] [Related]
31. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
[TBL] [Abstract][Full Text] [Related]
32. Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour.
Pinto AE; Silva GL; Henrique R; Menezes FD; Teixeira MR; Leite V; Cavaco BM
Eur J Endocrinol; 2014 Feb; 170(2):321-7. PubMed ID: 24272198
[TBL] [Abstract][Full Text] [Related]
33. A germline mutation (A339V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma.
Ngan ES; Lang BH; Liu T; Shum CK; So MT; Lau DK; Leon TY; Cherny SS; Tsai SY; Lo CY; Khoo US; Tam PK; Garcia-Barceló MM
J Natl Cancer Inst; 2009 Feb; 101(3):162-75. PubMed ID: 19176457
[TBL] [Abstract][Full Text] [Related]
34. Recurrent TP53 missense mutation in cancer patients of Arab descent.
Zick A; Kadouri L; Cohen S; Frohlinger M; Hamburger T; Zvi N; Plaser M; Avital E; Breuier S; Elian F; Salah A; Goldberg Y; Peretz T
Fam Cancer; 2017 Apr; 16(2):295-301. PubMed ID: 27866339
[TBL] [Abstract][Full Text] [Related]
35. Targeted next-generation sequencing in papillary thyroid carcinoma patients looking for germline variants predisposing to the disease.
Shen CT; Zhang GQ; Qiu ZL; Song HJ; Sun ZK; Luo QY
Endocrine; 2019 Jun; 64(3):622-631. PubMed ID: 30826992
[TBL] [Abstract][Full Text] [Related]
36. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
37. Identification of Rare Variants Predisposing to Thyroid Cancer.
Wang Y; Liyanarachchi S; Miller KE; Nieminen TT; Comiskey DF; Li W; Brock P; Symer DE; Akagi K; DeLap KE; He H; Koboldt DC; de la Chapelle A
Thyroid; 2019 Jul; 29(7):946-955. PubMed ID: 30957677
[No Abstract] [Full Text] [Related]
38. Determination of the mutational landscape in Taiwanese patients with papillary thyroid cancer by whole-exome sequencing.
Chang CC; Chang YS; Huang HY; Yeh KT; Liu TC; Chang JG
Hum Pathol; 2018 Aug; 78():151-158. PubMed ID: 29753010
[TBL] [Abstract][Full Text] [Related]
39. The Profile of Genetic Mutations in Papillary Thyroid Cancer Detected by Whole Exome Sequencing.
Fang Y; Ma X; Zeng J; Jin Y; Hu Y; Wang J; Liu R; Cao C
Cell Physiol Biochem; 2018; 50(1):169-178. PubMed ID: 30278442
[TBL] [Abstract][Full Text] [Related]
40. [Clinicopathologic and molecular features of cribriform morular variant of papillary thyroid carcinoma].
Cui XJ; Zhao HO; Su P; Chen J; Zhang RY; Pan Y; Ouyang XM; Liu J; Zhang JQ; Yang Y; Yang R; Ding L; Liu ZY
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):354-359. PubMed ID: 29783802
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
